Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone

被引：57

作者：

Cataldo, NA

Abbasi, F

McLaughlin, TL

Lamendola, C

Reaven, GM

机构：

[1] Stanford Univ, Med Ctr, Dept Gynecol & Obstet, Div Reprod Endocrinol & Infertil, Stanford, CA 94305 USA

[2] Stanford Univ, Med Ctr, Dept Gynecol & Obstet, Div Reprod Endocrinol & Infertil, Stanford, CA 94305 USA

[3] Stanford Univ, Med Ctr, Dept Med, Div Endocrinol Gerontol & Metab, Stanford, CA 94305 USA

[4] Shaman Pharmaceut, S San Francisco, CA USA

来源：

FERTILITY AND STERILITY | 2001年 / 76卷 / 05期

关键词：

polycystic ovary syndrome; insulin resistance; rosiglitazone; ovulation; pregnancy;

D O I：

10.1016/S0015-0282(01)02843-6

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Objective: To determine the metabolic and reproductive effectiveness of rosiglitazone in polycystic ovary syndrome (PCOS). Design: Case report. Setting: Academic clinical practice and General Clinical Research Center. Patient(s): A 25-year-old woman with PCOS. Intervention(s): Rosiglitazone maleate, 4 mg daily for 5 months until conception. Main Outcome Measure(s): Insulin sensitivity by steady-state plasma glucose technique; serum androgens, progesterone, and hCG; and pelvic ultrasound images. Result(s): Rosiglitazone. treatment for 5 months improved insulin sensitivity, lowered serum free testosterone, and resulted in spontaneous ovulation and conception. Conclusion(s): Rosiglitazone is a promising insulin sensitizer for treatment of PCOS. Clinical trials are warranted. (C) 2001 by American Society for Reproductive Medicine.

引用

页码：1057 / 1059

页数：3

共 4 条

[1] Insulin-lowering therapeutic modalities for polycystic ovary syndrome [J].